Andrew Adams at ARDD2025: Redrawing the Health Care Map: From Pushing at Boundaries to Redefining...

Andrew Adams at ARDD2025: Redrawing the Health Care Map: From Pushing at Boundaries to Redefining...

by Andrew Adams

Applied Sciences & Engineering Medicine & Health MBMedicineMBPHealth systems and services
🎙 Andrew Adams 👥 9K 📅 January 22, 2026 ⏱ 23 min 👁 232 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

aginghealthspanpreventionGLP-1Alzheimer's

Summary

Andrew Adams from Eli Lilly presents at ARDD2025 on the paradigm shift from sick care to health care, emphasizing prevention over treatment. He discusses the need for durable, convenient medicines to improve adherence, citing examples like statins, HPV vaccines, and GLP-1 agonists. He highlights Lilly’s work in Alzheimer’s disease, including the TRAILBLAZER-ALZ 2 trial results with donanemab, showing a 35% slowing of cognitive decline and 47% of patients with no clinical progression at one year. He advocates for earlier intervention and prevention trials like TRAILBLAZER-ALZ 3. He also covers GLP-1 drugs, including tirzepatide’s 94% reduction in progression from pre-diabetes to diabetes, and orforglipron as an oral option. He mentions new molecules like retatrutide and bimagrumab for muscle preservation. He calls GLP-1s the world’s first longevity drug, citing benefits beyond weight loss, including cardiovascular and neurodegenerative protection. He emphasizes the need for collaboration and answers questions on amyloid targeting, patient subpopulations, and genetic factors.

153 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable insights into the pharmaceutical industry’s perspective on aging and prevention, with specific data from clinical trials. The argumentation is coherent, moving from the concept of prevention to concrete examples and future directions. However, it is largely promotional, and the evidence is presented selectively, with limited discussion of limitations or alternative viewpoints.

Scientific Rigor, Source Quality, Title Accuracy

The talk references specific clinical trials and data, but does not provide detailed citations or sources. The title accurately reflects the content, which focuses on redefining healthcare boundaries. The scientific rigor is moderate, as the speaker is an industry representative with a potential conflict of interest. No external sources are cited, and the talk relies on internal company data.

129 words

Title / Content Match

The title accurately reflects the talk's focus on shifting healthcare from treatment to prevention, with examples from Alzheimer's and GLP-1 drugs.

Quality & Reliability

7/10

Presentation by an industry expert with specific data references, but limited independent verification and potential commercial bias.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • TRAILBLAZER-ALZ 2 trial — Cited as the source of donanemab efficacy data
  • TRAILBLAZER-ALZ 3 trial — Cited as ongoing prevention trial
  • SURPASS trials — Cited for tirzepatide data on diabetes and weight loss

Concurring Sources

  • Donanemab in Early Symptomatic Alzheimer Disease — Published trial results supporting the efficacy of donanemab.
  • Tirzepatide for the Treatment of Obesity — Clinical trial data on tirzepatide for weight loss.

Dissenting Sources

  • Concerns about GLP-1 side effects — Potential adverse effects not discussed in the talk.

Contribution & Novelties

The talk offers a corporate perspective on aging research, emphasizing prevention and the potential of GLP-1s as longevity drugs. It provides specific clinical data and future directions, but the novelty is limited as it aligns with existing industry trends.

Pour aller plus loin :

66 words

Radar Profile

The radar profile shows high scores in information quantity and quality, with moderate technical level and reliability. This indicates a well-informed but industry-biased presentation.

Reliability 7/10